Anyone see the rebates? Lawmakers accuse Mylan of underpaying Medicaid for EpiPen
(By Ed Silverman for ST A T) D id Mylan Pharmaceuticals misclassify EpiPen to avoid paying higher Medicaid rebates ?
Read More
Part D/Prescription Drugs
Hurdles abound in race to bring customized cancer treatments to masses
(By Meghana Keshavan for ST A T) T he idea is tantalizing: Reengineer a patient’s own immune cells to attack
Read MoreAn Even Deadlier Opioid, Carfentanil, Is Hitting The Streets
(By Jennifer Ludden for NPR) A powerful drug that’s normally used to tranquilize elephants is being blamed for a record
Read MoreTest Of Experimental Alzheimer’s Drug Finds Progress Against Brain Plaques
(By Jon Hamilton for NPR) An experimental drug dramatically reduced the toxic plaques found in the brains of patients with
Read MoreFDA Boosts Warning On Danger Of Combining Opioids And Anxiety Meds
(By Joe Neel for NPR) The Food and Drug Administration is warning that patients and doctors should more fully understand
Read MoreMylan’s Generic EpiPen — A Price Break Or Marketing Maneuver?
(By Julie Appleby for Kaiser Health News) Following weeks of criticism over dramatic price increases on its EpiPen, Mylan said
Read MoreFDA to hold long-awaited meeting to review off-label marketing
(By Ed Silverman for ST A T) After years of anticipation, the US Food and Drug Administration will hold a
Read MoreCalifornia court hangs out a welcome sign: Drug makers can be sued here
(By Ed Silverman for ST A T) In a closely watched decision, the California Supreme Court ruled 4-3 Monday that
Read MoreAnother Biosimilar Wins FDA Approval
U.S. Food and Drug Administration (FDA) approved Novartis’s Sandoz drug Erelzi (biosimilar copy of Amgen’s Enbrel) on Tuesday but it
Read MoreMaker Of EpiPen To Sell Generic Version For Half The Price
(By Alison Kodjak for NPR) Treatment for life-threatening allergic reactions is about to get a little cheaper. Mylan, the maker
Read More